Literature DB >> 10693969

Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy.

C Meijer1, E G de Vries, P Marmiroli, G Tredici, L Frattola, G Cavaletti.   

Abstract

The mechanism(s) and site(s) of the neurotoxic effect of cisplatin (CDDP) are still not entirely elucidated. A more detailed knowledge of these aspects of CDDP treatment might be useful to obtain a better understanding of the pathogenesis of its peripheral neurotoxicity, which is the dose-limiting side effect of CDDP. In the present study, the occurrence of CDDP-induced DNA-platination in dorsal root ganglia (DRG) of rats was evaluated in relation to DRG neuron pathological changes and CDDP-induced neuronopathy. Eight adult Wistar rats were treated with 2 mg/kg i.p. CDDP twice weekly for 9 times to induce sensory peripheral neuropathy. DNA-platination in specimens of DRG and kidney was measured immunohistochemically, with a polyclonal antibody (GPt) detecting CDDP-induced Pt-DNA adducts. Results were compared with those of untreated rats. Chronic CDDP-induced neurotoxicity, in a well described experimental model of chronic CDDP neurotoxicity in the Wistar rat, was confirmed by sensory DRG neuronopathy with secondary neuropathy, and demonstrated by reduced pain detection, decreased nerve conduction velocity in the tail nerve as well as morphological and morphometric changes in DRG neurons. Nuclear immunostaining for Pt-DNA adducts was observed in tubular cells of the kidney in 75% of the evaluated CDDP-treated rats, while in DRG cells CDDP-induced Pt-DNA adducts formation was found in 43% of the evaluated CDDP-treated rats. CDDP-induced DNA-platination was demonstrated in rat DRG neurons using a schedule of chronic CDDP administration which induced the onset of a sensory neuronopathy with secondary peripheral neuropathy. This finding further supports the hypothesis that CDDP is neurotoxic because it directly damages the DRG neurons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10693969

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  30 in total

1.  Drosophila melanogaster: a new model to study cisplatin-induced neurotoxicity.

Authors:  Jewel L Podratz; Nathan P Staff; Dara Froemel; Anna Wallner; Florian Wabnig; Allan J Bieber; Amy Tang; Anthony J Windebank
Journal:  Neurobiol Dis       Date:  2011-04-15       Impact factor: 5.996

Review 2.  Peripheral neuropathy in children and adolescents treated for cancer.

Authors:  Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness
Journal:  Lancet Child Adolesc Health       Date:  2018-09-01

Review 3.  Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy.

Authors:  Joyce H Kim; Patrick M Dougherty; Salahadin Abdi
Journal:  Gynecol Oncol       Date:  2015-01-10       Impact factor: 5.482

Review 4.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

5.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

6.  Recombinant human erythropoietin counteracts cisplatin-induced visceral hyperalgesia.

Authors:  Min-Suk Yoon; Lars Bechmann; Mark Obermann; Olivia Yepnjouo; Rupert Egensperger; Guido Gerken; Zaza Katsarava; Juergen Thomale; Gerald Holtmann
Journal:  Neurosci Bull       Date:  2010-08       Impact factor: 5.203

7.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

8.  Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy.

Authors:  Anna Dzagnidze; Zaza Katsarava; Julia Makhalova; Bernd Liedert; Min-Suk Yoon; Holger Kaube; Volker Limmroth; Juergen Thomale
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

9.  Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Authors:  Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

10.  Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.

Authors:  Stephen M F Jamieson; Joshuan Subramaniam; Johnson J Liu; Nancy N Jong; Virginia Ip; Bronwen Connor; Mark J McKeage
Journal:  Mol Pain       Date:  2009-11-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.